<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00480402</url>
  </required_header>
  <id_info>
    <org_study_id>VLC-VS-0405-507-23</org_study_id>
    <nct_id>NCT00480402</nct_id>
  </id_info>
  <brief_title>Natural Progesterone and Preterm Birth in Twins</brief_title>
  <official_title>Eficacia de Los Suplementos de Progesterona Natural en la prevención Del Parto pretérmino Gemelar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effectiveness of natural progesterone supplementation in preventing preterm
      births in twins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To assess the effectiveness of natural progesterone supplementation in preventing
      preterm births in twins.

      Study Design: National multicenter randomized double blind controlled clinical trial.

      Setting: Six tertiary hospitals in the east of Spain (communities of Valencia and Murcia):
      Instituto Universitario IVI Valencia, Hospital Universitario La Fe (Valencia), Hospital
      Universitario Dr. Peset (Valencia), Hospital General Universitario (Alicante), Hospital Vega
      Baja de Orihuela (Alicante) y Hospital Virgen de la Arrixaca (Murcia).

      Population: 246 bichorionic biamniotic twin pregnant women divided in three groups according
      to the allocated randomized treatment: (I) placebo (N=82); (II) 200 mg progesterone (N=82);
      and (III) 400 mg progesterone (N=82).

      Methods: All participant women will self-administer two vaginal pessaries at bedtime
      containing the allocated treatment. Vaginal pessaries will be identical externally but will
      contain either placebo or 200 mg of natural progesterone (Laboratorios Effik, Madrid, Spain).
      The treatment will be applied from the 20th week until the 34th week (or until delivery if it
      occurred earlier). Control visits will be performed at 24, 28, 32 and 34 weeks. Pregnancies
      will be managed according to each local protocol. An external statistical analysis will be
      performed on intention to treat basis.

      Main outcome measure: Preterm birth rate (&lt;37 weeks). Secondary outcome measures: very
      preterm birth rate (&lt;32 weeks); cervical length measured by vaginal ultrasound at each
      control visit; need for tocolytic treatments; rate of preterm premature rupture of membranes;
      and perinatal morbidity and mortality.

      Estimated period of study: 2006-2008.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Preterm Birth</condition>
  <arm_group>
    <arm_group_label>400 mg Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 400 mg Progesterone Group vaginal pessaries arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Progesterone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 200 mg Progesterone Group vaginal pessaries arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Approximately one third of the bichoronic biamniotic twin pregnant women were randomized to the placebo vaginal pessaries arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg of Progesterone</intervention_name>
    <description>Administration of 200 mg of Progesterone</description>
    <arm_group_label>200 mg Progesterone Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg Progesterone</intervention_name>
    <description>Administration of 400 mg Progesterone</description>
    <arm_group_label>400 mg Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of a Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bichorionic biamniotic twin pregnant women

          -  = or &gt; 18 years old

        Exclusion Criteria:

          -  Single pregnancy or monochorionic twin pregnancy or triplets

          -  Chronic hepatic pathology, previous alterations in hepatic analysis during
             anti-contraceptive treatment; or gestational cholestasis in in previous
             pregnancies.Basal alterations in hepatic analysis profile.

          -  Profylactic cerclage until week 14.

          -  Basal alterations in renal analysis profile

          -  Local allergy to micronized natural progesterone

          -  Genital pathology not allowing for correct absorption of medication

          -  Fetal anomoly diagnosed after sonograph week 12 and/or 20.

          -  Smokers of more than 10 cigarettes/day

          -  Consumers of illegal substances
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Serra, MDPhD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Valenciano de la Infertilidad</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Valenciano de la Infertilidad</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2007</study_first_submitted>
  <study_first_submitted_qc>May 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2007</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <keyword>preterm birth</keyword>
  <keyword>progesterone</keyword>
  <keyword>twins</keyword>
  <keyword>Preterm birth in twin gestations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

